Evidence map›Paper›PMID 33604539›Full record

ArticleKidney medicine

Self-reported Pruritus and Clinical, Dialysis-Related, and Patient-Reported Outcomes in Hemodialysis Patients.

Nidhi Sukul, Angelo Karaboyas, Philipp A Csomor, Thilo Schaufler, Warren Wen, Frédérique Menzaghi, Hugh C Rayner, Takeshi Hasegawa, Issa Al Salmi, Saeed M G Al-Ghamdi and 3 more

Abstract read
In one paragraph

Article in Kidney medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
92citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

92 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Difelikefalin improves itch-related sleep disruption in patients undergoing haemodialysis.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024
    Trial
  12. Trial
  13. Article
  14. Article
  15. Observational
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

32 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Nidhi SukulDivision of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI.
Angelo KaraboyasArbor Research Collaborative for Health, Ann Arbor, MI.
Philipp A CsomorVifor Pharma Ltd, Glattbrugg, Switzerland.
Thilo SchauflerVifor Pharma Ltd, Glattbrugg, Switzerland.
Warren WenCara Therapeutics, Inc, Stamford, CT.
Frédérique MenzaghiCara Therapeutics, Inc, Stamford, CT.
Hugh C RaynerDepartment of Renal Medicine, University Hospitals Birmingham NHS FT, United Kingdom.
Takeshi HasegawaShowa University Research Administration Center; Department of Hygiene, Public Health and Preventive Medicine, Graduate School of Medicine, Tokyo, Japan.
Issa Al SalmiDepartment of Renal Medicine, Royal Hospital, Muscat, Oman.
Saeed M G Al-GhamdiDepartment of Medicine, College of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
Fitsum Guebre-EgziabherService de Néphrologie, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France.
Pablo-Antonio Ureña-TorresDepartment of Dialysis, AURA Nord Saint Ouen, Paris, France.
Ronald L PisoniArbor Research Collaborative for Health, Ann Arbor, MI.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RATIONALE &

objectiveChronic kidney disease (CKD)-associated pruritus, generalized itching related to CKD, affects many aspects of hemodialysis patients' lives. However, information regarding the relationship between pruritus and several key outcomes in hemodialysis patients remains limited. STUDY

designProspective cohort. SETTING &

participants23,264 hemodialysis patients from 21 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS) phases 4 to 6 (2009-2018). EXPOSURE: Pruritus severity, based on self-reported degree to which patients were bothered by itchy skin (5-category ordinal scale from "not at all" to "extremely"). OUTCOMES: Clinical, dialysis-related, and patient-reported outcomes. ANALYTICAL APPROACH: Cox regression for time-to-event outcomes and modified Poisson regression for binary outcomes, adjusted for potential confounders.

resultsThe proportion of patients at least moderately bothered by pruritus was 37%, and 7% were extremely bothered. Compared with the reference group ("not at all"), the adjusted mortality HR for patients extremely bothered by pruritus was 1.24 (95% CI, 1.08-1.41). Rates of cardiovascular and infection-related deaths and hospitalizations were also higher for patients extremely versus not at all bothered by pruritus (HR range, 1.17-1.44). Patients extremely bothered by pruritus were also more likely to withdraw from dialysis and miss hemodialysis sessions and were less likely to be employed. Strong monotonic associations were observed between pruritus severity and longer recovery time from a hemodialysis session, lower physical and mental quality of life, increased depressive symptoms, and poorer sleep quality. LIMITATIONS: Residual confounding, recall bias, nonresponse bias.

conclusionsOur findings demonstrate how diverse and far-reaching poor outcomes are for patients who experience CKD-associated pruritus, specifically those with more severe pruritus. There is need for change in practice patterns internationally to effectively identify and treat patients with pruritus to reduce symptom burden and improve quality of life and possibly even survival.

Indexed as

hemodialysispatient-reported outcomespruritusquality of life

Identifiers

PMID33604539
PMCPMC7873756

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.